Abstract
The question whether aging is a disease or not, has been asked by many professionals who are involved in the study of age-related degeneration. However, not only an agreement on this remains elusive, but also effective clinical treatments against human aging have not been forthcoming. In this Opinion paper I suggest that the complexity involved in aging is such that we need to remodel our thinking to involve a much more ‘systems-oriented’ approach. I explore four main principles which should be employed by those who are working on finding treatments against agerelated degeneration. First, I discuss the problems encountered in translating laboratory research into effective therapies for humans. Second, I propose that a ‘systems-thinking’ method needs to be more extensively employed, instead of relying exclusively on the current reductionist one. Third, it is submitted that we must learn from the history of life-extension research, and not blindly follow contemporary paradigms, which may lead us into yet more ‘dead ends’ with regards to therapies. Finally, I suggest that, we may need to employ certain universal notions and use these in order to gain insights into the mechanics of a possible therapy against age-related degeneration. Examples may be the principle of hormesis, those of degeneracy, exaptation, and others from cybernetic or systems science domains. By using this four-pronged approach we liberate our thinking from the shackles of existing common mistakes and fallacies, and we open the way for a fresh approach that may lead us towards entirely new paradigms for providing clinically effective therapies against agerelated degeneration.
Keywords: Reductionism, systems thinking, translational research, age-related degeneration, life extension, hormesis.
Graphical Abstract
[1]
Kyriazis M. Neurons vs. Germline: A war of hormetic tradeoffs. Curr Aging Sci 2017; 10(4): 242-5.
[2]
Kyriazis M. Editorial: Novel approaches to an old problem: Insights, theory and practice for eliminating aging. Curr Aging Sci 2014; 7(1): 1-2.
[3]
Kyriazis M, Apostolides A. The fallacy of the longevity elixir: Negligible senescence may be achieved, but not by using something physical. Curr Aging Sci 2015; 8(3): 227-34.
[4]
Kyriazis M. The impracticality of biomedical rejuvenation therapies: Translational and pharmacological barriers. Rejuvenation Res 2014; 17(4): 390-6.
[5]
Callahan CM, Foroud T, Saykin AJ, et al. Translational research on aging: Clinical epidemiology as a bridge between the sciences. Translatl Res J Lab Clin Med 2014; 163(5): 439-45.
[6]
Schully SD, Khoury MJ. What is translational genomics? An expanded research agenda for improving individual and population health. Appl Transl Genomics 2014; 3(4): 82-3.
[7]
De Grey AD. Rejuvenation biotechnology: The industry emerges, but short-termism looms. Rejuvenation Res 2016; 19(3): 193-4.
[8]
Kyriazis M. Editorial: Re-thinking ageing: A cross-disciplinary perspective (A New Era for Ageing). Mech Ageing Dev 2017; 163: 1.
[9]
Heneghan C, Goldacre B, Mahtani KR. Why clinical trial outcomes fail to translate into benefits for patients. Trials 2017; 18: 122.
[10]
Abernethy AP, Wheeler JL. True translational research: Bridging the three phases of translation through data and behavior. Transl Behav Med 2011; 1(1): 26-30.
[11]
Hackam DG. Translating animal research into clinical benefit. BMJ British Med J 2007; 334(7586): 163-4.
[12]
Hu HY, Guo S, Xi J, et al. MicroRNA expression and regulation in human, chimpanzee, and macaque brains. PLoS Genet 2011; 7(10): e1002327.
[13]
Dweep H, Georgiou GD, Gretz N, et al. CNVs-microRNAs Interactions Demonstrate unique characteristics in the human genome. An interspecies in silico analysis. PLoS One 2013; 8(12): e81204.
[14]
Henney AM. The promise and challenge of personalized medicine: Aging populations, complex diseases, and unmet medical need. Croat Med J 2012; 53(3): 207-10.
[15]
Zealley B, de Grey ADNJ. Commentary on some recent theses relevant to combating aging. Rejuvenation Res 2018; 21(1): 70-6.
[16]
Flood RL. The relationship of ‘systems thinking’ to action research. Syst Pract Action Res 2010; 23: 269-84.
[17]
Necka EA, Cacioppo S, Cacioppo JT. Social neuroscience of the twenty-first century The University of Chicago, Chicago, IL, USA,. 2015.
[18]
Cacioppo JT. Berntson. Social psychological contributions to the decade of the brain: Doctrine of multilevel analysis. Am Psychol 1992; 47: 1019-28.
[19]
Kyriazis M. Third phase science: Defining a novel model of research into human ageing. Front Biosci (Landmark Ed) 2017; 22: 982-90.
[20]
Cole SW. Social regulation of human gene expression: Mechanisms and implications for public health. Am J Public Health 2013; 103(S1): S84-92.
[21]
Grewenb KM, Coffeya KA, Algoea SB, et al. A functional genomic perspective on human well-being. Proc Natl Acad Sci USA 2013; 110: 33.
[22]
Richerson P, Boyd R, Henrich J. Gene-culture coevolution in the age of genomics. In the Light of Evolution: Volume IV: The Human Condition. National Academies Press: OpenBook, 2010
[24]
Mohler J, Najafi B, Fain M, et al. Precision medicine: A wider definition. J Am Geriatr Soc 2015; 63(9): 1971-2.
[25]
Ogino S, Lochhead P, Chan AT. Molecular pathological epidemiology of epigenetics: Emerging integrative science to analyze environment, host, and disease. Mod Pathol 2013; 26(4): 465-84.
[26]
Ogino S, Fuchs CS, Giovannucci E. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn 2012; 12(6): 621-8.
[27]
Bromley DB. The idea of ageing: An historical and psychological analysis. Compr Gerontol [C] 1988; 2(1): 30-41.
[29]
Peterson M, Rose CL. Historical antecedents of normative vs pathologic perspectives in aging. J Am Geriatr Soc 1982; 30(4): 289-94
[30]
De Grey A, Rae M Ending Aging: The rejuvenation breakthroughs that could reverse human aging in our lifetime 2007 New York, NY: St Martin's Press ISBN 0-312-36706-6
[32]
Naaldenberg J. Healthy aging in complex environments 2011 Thesis, Wageningen University, Wageningen, NL. Availabl at.http://edepot.wur.nl/169511
[33]
Clarke P, Nieuwenhuijsen R. Environments for healthy ageing: A critical review. Maturitas 2009; 64(1): 14-9.
[34]
Haber C. Life extension and history: The continual search for the fountain of youth. J Gerontol A Biol Sci Med Sci 2004; 59(6): B515-22.
[35]
Ritch A. History of geriatric medicine: From hippocrates to marjory warren. J R Coll Physicians Edinb 2012; 42(4): 368-74.
[36]
Palm R, Chang J, Blair J, et al. Down-regulation of serum gonadotropins but not estrogen replacement improves cognition in aged-ovariectomized 3xTg AD female mice. J Neurochem 2014; 130(1): 115-25.
[37]
Fanaei H, Karimian SM, Sadeghipour HR, et al. Testosterone enhances functional recovery after stroke through promotion of antioxidant defenses, BDNF levels and neurogenesis in male rats. Brain Res 2014; 1558: 74-83.
[38]
Hogan CL, Mata J, Carstensen LL. Exercise holds immediate benefits for affect and cognition in younger and older adults. Psychol Aging 2013; 28(2): 587-94.
[39]
Kyriazis M. Biological ageing and clinical consequences of modern technology. Biogerontology 2017; 18(4): 711-5.
[40]
Mason PH. Degeneracy: Demystifying and destigmatizing a core concept in systems biology. Complexity 2015; 20(3): 12-21.
[41]
Mason PH, Domínguez DJF, Winter GA. Hidden in plain view: Degeneracy in complex systems. Biosystems 2015; 128: 1-8.
[42]
Cropper EC, Dacks AM, Weiss KR. Consequences of degeneracy in network function. Curr Opin Neurobiol 2016; 41: 62-7.
[43]
Gally JA. Degeneracy and complexity in biological systems. Proc Natl Acad Sci 2001; 98(24): 13763-8.
[44]
Whitacre JM. Degeneracy: A link between evolvability, robustness and complexity in biological systems. Theor Biol Med Model 2010; 7(6): 6.
[45]
Calabrese EJ, Mattson MP. How does hormesis impact biology, toxicology, and medicine? NPJ Aging Mech Dis 2017; 3: 13.
[48]
Pardon MC. Hormesis is applicable as a pro-healthy aging intervention in mammals and human beings. Dose Response 2010; 8(1): 22-7.
[49]
Martucci M, Ostan R, Biondi F, et al. Mediterranean diet and inflammaging within the hormesis paradigm. Nutr Rev 2017; 75(6): 442-55.
[50]
Calabrese EJ, Dhawan G, Kapoor R, et al. What is hormesis and its relevance to healthy aging and longevity? Biogerontology 2015; 16(6): 693-707.
[51]
Kim B, Brandli A, Mitrofanis J, et al. Remote tissue conditioning- An emerging approach for inducing body-wide protection against diseases of ageing. Ageing Res Rev 2017; 37: 69-78.
[53]
Longo VD, Antebi A, Bartke A, et al. Interventions to slow aging in humans: Are we ready? Aging Cell 2015; 14(4): 497-510.
[54]
Liu GH, Ding Z, Izpisua BJC. iPSC technology to study human aging and aging-related disorders. Curr Opin Cell Biol 2012; 24(6): 765-74.
[55]
De Magalhães JP. The scientific quest for lasting youth: Prospects for curing aging. Rejuvenation Res 2014; 17(5): 458-67.
[56]
Yener IB, Cagin U, Yilmazer A. Cellular reprogramming: A new way to understand aging mechanisms. Wiley Interdiscip Rev Dev Biol 2018; 7(2)
[http://dx.doi.org/10.1002/wdev.308]
[http://dx.doi.org/10.1002/wdev.308]
[57]
Nurkovic J, Volarevic V, Lako M, et al. Aging of stem and progenitor cells: Mechanisms, impact on therapeutic potential, and rejuvenation. Rejuvenation Res 2016; 19(1): 3-12.
[59]
Weinberg BA, Marshall JL, Hartley M, et al. A paradigm shift from one-size-fits-all to tailor-made therapy for metastatic colorectal cancer. Clin Adv Hematol Oncol 2016; 14(2): 116-28.
[60]
Davis OK, Rosenwaks Z. Personalized medicine or “one size fits all”? Fertil Steril 2014; 101(4): 922-3.
[62]
Piazza JR, Charles ST, Luong G, et al. One size fits all? Applying theoretical predictions about age and emotional experience to people with functional disabilities. Psychol Aging 2015; 30(4): 930-9.
[63]
Terrera GM, Brayne C, Matthews F. CC75C study collaboration group. One size fits all? Why we need more sophisticated analytical methods in the explanation of trajectories of cognition in older age and their potential risk factors. Int Psychogeriatr 2010; 22(2): 291-9.
[64]
Marusic U, Grosprêtre S. Non-physical approaches to counteract age-related functional deterioration: Applications for rehabilitation and neural mechanisms. Eur J Sport Sci 2018; 20: 1-11.
[65]
Nowak S, Neidhart J, Szendro IG, et al. Interaction analysis of longevity interventions using survival curves. Biology (Basel) 2018; 7(1): pii: E6.
[66]
Kirkwood TB. Systems biology of ageing and longevity. Philos Trans R Soc Lond B Biol Sci 2011; 366(1561): 64-70.
[67]
Roukos DH. Longevity with systems medicine? Epigenome, genome and environment interactions network. Epigenomics 2012; 4(2): 119-23.
[68]
Cevenini E, Bellavista E, Tieri P, et al. Systems biology and longevity: An emerging approach to identify innovative anti-aging targets and strategies. Curr Pharm Des 2010; 16(7): 802-13.
[69]
McMurphy T, Huang W, Queen NJ, et al. Implementation of environmental enrichment after middle age promotes healthy aging. Aging (Albany NY) 2018; 10(7): 1698-721.
[70]
Bonfiglio T, Vergassola M, Olivero G, et al. Environmental training and synaptic functions in young and old brain: A presynaptic perspective. Curr Med Chem 2018.
[http://dx.doi.org/10.2174/0929867325666180228170450]
[http://dx.doi.org/10.2174/0929867325666180228170450]
[71]
Zuelsdorff ML, Koscik RL, Okonkwo OC, et al. Social support and verbal interaction are differentially associated with cognitive function in midlife and older age. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn 2017; 15: 1-17.
[72]
Sale A. A systematic look at environmental modulation and its impact in brain development. Trends Neurosci 2018; 41(1): 4-17.
[73]
Zhang T, Tan H. Molecular pathological epidemiology. Zhonghua Liu Xing Bing Xue Za Zhi 2015; 36(7): 762-4.
[74]
Nishi A, Kawachi I, Koenen KC, et al. Lifecourse epidemiology and molecular pathological epidemiology. Am J Prev Med 2015; 48(1): 116-9.
[75]
Nishihara R, VanderWeele TJ, Shibuya K, et al. Molecular pathological epidemiology gives clues to paradoxical findings. Eur J Epidemiol 2015; 30(10): 1129-35.
[76]
Burke W, Appelbaum P, Dame L, et al. The translational potential of research on the ethical, legal, and social implications of genomics. Genet Med 2015; 17(1): 12-20.
[77]
Cardoso SD, Teles MC, Oliveira RF. Neurogenomic mechanisms of social plasticity. J Exp Biol 2015; 218(Pt 1): 140-9.
[78]
Duster T. Social diversity in humans: Implications and hidden consequences for biological research. Cold Spring Harb Perspect Biol 2014; 6(5): a008482.
[79]
Hood L, Balling R, Auffray C. Revolutionizing medicine in the 21st century through systems approaches. Biotechnol J 2012; 7(8): 992-1001.
[80]
Hood L. Systems biology and p4 medicine: Past, present, and future. Rambam Maimonides Med J 2013; 4(2): e0012.
[81]
Wafi A, Mirnezami R. Translational omics: Future potential and current challenges in precision medicine. Methods 2018; 151: 3-11.
[82]
Snyderman R. Personalized medicine 2014: Has healthcare been transformed? Per Med 2014; 11(4): 365-8.
[83]
Zhou L, Wang K, Li Q, et al. Clinical proteomics-driven precision medicine for targeted cancer therapy: Current overview and future perspectives. Expert Rev Proteomics 2016; 13(4): 367-81.
[85]
Smith AD. Proteomic advances hold promise for precision medicine. Am J Manag Care 2014; 20(5 Spec No.): E14.
[86]
Empey PE. Pharmacogenomics to achieve precision medicine. Am J Health Syst Pharm 2016; 73(23): 1906-7.
[87]
Shapiro SD. The promise of precision medicine for health systems. Am J Health Syst Pharm 2016; 73(23): 1907-8.
[88]
Turgeon M, Lustig C, Meck WH. Cognitive aging and time perception: Roles of bayesian optimization and degeneracy. Front Aging Neurosci 2016; 8: 102.
[90]
Larson G, Stephens PA, Tehrani JJ, et al. Exapting exaptation. Trends Ecol Evol 2013; 28(9): 497-8.
Related Books
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Frontiers in Clinical Drug Research-Dementia
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Article Metrics
42
3
1